Prepares Clinical Trial Data at Record Pace for Faster Healthcare Breakthroughs with Trifacta
In overhead costs will be saved each year
Reduction in turnaround time for clinical studies
Increase in prediction accuracy
On any given day, IQVIA manages patient data for up to 70 different clinical studies run by government agencies, pharmaceutical companies and academic institutions. Under legacy tools and processes like SAS, copying this data into a single system from 250 unique vendor warehouses took days, while standardizing the data into FDA-compliant formats required 1 to 2 months. As the data generated from clinical trials came in at a faster rate and became increasingly non-identified and unstructured, IQVIA risked more significant delays, which would stall their clients’ progress.
How Trifacta Solved this Problem:
IQVIA now operates upon a centralized data platform that includes Streamsets for data integration and Trifacta for data engineering. This new analytic stack has allowed IQVIA to drastically reduce its delivery times from 1 to 2 months down to 1 to 2 days. Instead of relying on in-house developers, Trifacta’s intuitive approach to data transformation has allowed IQVIA to scale its efforts through domain experts who are adept at spotting patterns and data quality issues. And even though patient data has grown larger and more complex, IQVIA has seen a 4X increase in prediction accuracy. As patient data continues to take on new forms, IQVIA can make simple adjustments to its Trifacta recipes while maintaining the same delivery speed.
Faster Time to Value
With Trifacta, IQVIA reduced the turnaround time of executing analysis for their clients by 92%
Once this process is adopted across all new and existing clinical trials, IQVIA will save $1.2 million a year by automating these analytics.
IQVIA has seen an increase in prediction accuracy by four times. This has helped IQVIA better match patients to trials and accelerate the pace of discovery.
IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare – and human health – forward.
“In total, the overall turnaround time has been reduced by 92 percent for every new clinical studies data our team receives. Additionally, we’ve seen an increase in prediction accuracy by four times its original rate. This has not only helped the company achieve its mission of finding the right patient for the ideal clinical trial, but has increasingly accelerated the pace of discovery.”